28072 Federal Register / Vol. 72, No. 96 / Friday, May 18, 2007 / Notices 

Cambrex Charles City, Inc. to import the 

basic class of controlled substance is 

consistent with the public interest and 

with United States obligations under 

international treaties, conventions, or 

protocols in effect on May 1, 1971, at 

this time. DEA has investigated 

Cambrex Charles City, Inc. to ensure 

that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with State and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic class of controlled substance 

listed. 

Dated: May 14, 2007. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E7–9609 Filed 5–17–07; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated October 25, 2006, and 

published in the Federal Register on 

November 1, 2006, (71 FR 64298), 

Cambrex Charles City, Inc., 1205 11th 

Street, Charles City, Iowa 50616, made 

application by letter to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

Sufentanil (9740), a basic class of 

controlled substance listed in schedule 

II. 

The company plans to manufacture 

the listed controlled substances in bulk 

for distribution to its customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Cambrex Charles City, Inc. to 

manufacture the listed basic class of 

controlled substance is consistent with 

the public interest at this time. DEA has 

investigated Cambrex Charles City, Inc. 

to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 

of the company’s compliance with State 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: May 14, 2007. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E7–9625 Filed 5–17–07; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated January 16, 2007, and 

published in the Federal Register on 

January 23, 2007, (72 FR 2907), 

Cedarburg Pharmaceuticals, Inc., 870 

Badger Circle, Grafton, Wisconsin 

53024, made application by renewal to 

the Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the basic classes of 

controlled substances listed in schedule 

I and II: 

Drug Schedule 

Tetrahydrocannabinols (7370) ..... I 

Dihydromorphine (9145) ............... I 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Hydrocodone (9193) ..................... II 

Sufentanil (9740) .......................... II 

Fentanyl (9801) ............................ II 

Remifentanil (9739) ...................... II 

The company plans to manufacture 

the listed controlled substances in bulk 

for distribution to its customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Cedarburg Pharmaceuticals, Inc. to 

manufacture the listed basic class of 

controlled substance is consistent with 

the public interest at this time. DEA has 

investigated Cedarburg Pharmaceuticals, 

Inc. to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 

of the company’s compliance with State 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: May 14, 2007. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E7–9642 Filed 5–17–07; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated November 21, 2006, 

and published in the Federal Register 

on December 1, 2006, (71 FR 69589–

69590), Chattem Chemicals, Inc., 3801 

St. Elmo Avenue, Building 18, 

Chattanooga, Tennessee 37409, made 

application by renewal and by letter to 

the Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the basic classes of 

controlled substances listed in schedule 

I and II: 

Drug Schedule 

4–Methoxyamphetamine (7411) ... I 

Dihydromorphine (9145) ............... I 

Difenoxin (9168) ........................... I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Methylphenidate (1724) ................ II 

Pentobarbital (2270) ..................... II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Hydrocodone (9193) ..................... II 

Meperidine (9230) ........................ II 

Dextropropoxyphene, bulk (nondosage forms) (9273).II 

Morphine (9300) ........................... II 

Thebaine (9333) ........................... II 

Oxymorphone (9652) ................... II 

Noroxymorphone (9668) .............. II 

Alfentanil (9737) ........................... II 

Sufentanil (9740) .......................... II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

the listed controlled substances in bulk 

for distribution to its customers. 

By letter dated February 15, 2007, 

Chattem Chemicals has withdrawn their 

request for N-Ethylamphetamine (1475), 

Secobarbital (2315), 2,5–

Dimethoxyamphetamine (7396), 

Diphenoxylate (9170), Opium Extracts 

(9610), Opium Fluid Extract (9620), 

Opium Tincture (9630), Opium 

Powdered (9639), and Opium 

Granulated (9640). 

One comment has been received; this 

comment has been noted and 

considered by DEA. 


pwalker on PROD1PC71 with NOTICES